Market capitalization of U.S. biotech companies by region 2021
This statistic shows the market capitalization of public biotech companies in 2021, sorted by major U.S. region. New York's total market capitalization of all public biotech companies came to approximately 86.5 billion U.S. dollars as of year-end 2021.
U.S. public biotech companies
Massachusetts and Northern California have some of the most successful public biotechnology companies in the United States, totaling some 345 billion U.S. dollars and 280 billion U.S. dollars in market capitalization, respectively, as of year-end 2021. Unsurprisingly, these two regions also have the greatest number of public biotech companies, totaling 152 in Massachusetts and 107 in Northern California. However, both regions saw an increase in the number of these public companies compared to the previous year. These two regions are also spending the highest amount on research and development endeavors. Within Northern California, the San Francisco Bay Area is considered the birth place of biotechnology, being the home to a large number of research universities and federal research institutions. It employs around half of California’s biomedical employees.
U.S. public biotech companies
Massachusetts and Northern California have some of the most successful public biotechnology companies in the United States, totaling some 345 billion U.S. dollars and 280 billion U.S. dollars in market capitalization, respectively, as of year-end 2021. Unsurprisingly, these two regions also have the greatest number of public biotech companies, totaling 152 in Massachusetts and 107 in Northern California. However, both regions saw an increase in the number of these public companies compared to the previous year. These two regions are also spending the highest amount on research and development endeavors. Within Northern California, the San Francisco Bay Area is considered the birth place of biotechnology, being the home to a large number of research universities and federal research institutions. It employs around half of California’s biomedical employees.
